人民财讯1月2日电，诺诚健华今日宣布，公司自主研发的新型TYK2抑制剂soficitinib（ICP-332）的临床研究获得重大进展，治疗中重度特应性皮炎（AD）的III期注册临床试验已完成患者入组，标志着soficitinib解决AD疾病迈出了关键一步。与此同时，soficitinib治疗白癜风的II期临床试验也已经完成患者入组。
（文章来源：人民财讯）
人民财讯1月2日电，诺诚健华今日宣布，公司自主研发的新型TYK2抑制剂soficitinib（ICP-332）的临床研究获得重大进展，治疗中重度特应性皮炎（AD）的III期注册临床试验已完成患者入组，标志着soficitinib解决AD疾病迈出了关键一步。与此同时，soficitinib治疗白癜风的II期临床试验也已经完成患者入组。
（文章来源：人民财讯）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.